1. What is the projected Compound Annual Growth Rate (CAGR) of the AI for Drug Discovery and Development?
The projected CAGR is approximately 5%.
AI for Drug Discovery and DevelopmentAI for Drug Discovery and Development Charting Growth Trajectories: Analysis and Forecasts 2025-2033
AI for Drug Discovery and Development by Type (Target Identification, Molecule Screening, De Novo Drug Design and Drug Optimization, Preclinical and Clinical Testing, Others), by Application (Oncology, Infectious Disease, Neurology, Others), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast 2025-2033
Base Year: 2024
136 Pages
AI for Drug Discovery and Development Charting Growth Trajectories: Analysis and Forecasts 2025-2033
AI for Drug Discovery and Development Charting Growth Trajectories: Analysis and Forecasts 2025-2033
Key Insights
The AI for Drug Discovery and Development market is projected to grow from a valuation of USD 3,555.5 million in 2023 to reach USD 8,382.4 million by 2033, exhibiting a CAGR of 5% during the forecast period. AI technologies in drug discovery and development have gained traction due to their efficiency in identifying potential drug candidates, optimizing lead compounds, and predicting clinical trial outcomes. This market growth is fueled by factors such as rising healthcare costs, increasing prevalence of chronic diseases, and the need for personalized medicine. Additionally, the integration of artificial intelligence (AI) and machine learning (ML) algorithms in drug discovery processes has enabled the analysis of vast amounts of data, leading to more accurate predictions and reduced drug development timelines. This convergence of AI and drug discovery has sparked a surge in investment and strategic partnerships among pharmaceutical companies and AI solution providers.
Key players operating in the AI for Drug Discovery and Development market include Alphabet, Atomwise, BenevolentAI, Cloud Pharmaceutical, Deep Genomics, Exscientia, IBM, Insilico Medicine, Microsoft Corporation, Nvidia Corporation, XtalPi, DP Technology, Tencent iDrug, PaddleHelix, EIHealth, Aliyun, and others. These companies are investing heavily in research and development to enhance their AI capabilities and expand their product offerings. North America is expected to hold the largest share of the global AI for Drug Discovery and Development market, owing to the presence of leading pharmaceutical companies and well-established healthcare infrastructure. However, Asia-Pacific is expected to witness significant growth in the coming years, driven by rising healthcare expenditure in developing countries such as China and India.
AI for Drug Discovery and Development Trends
The AI for drug discovery and development market is rapidly growing, with a market size of $1.3 billion in 2021 and an expected growth rate of 25.5% between 2022 and 2028. This growth is being driven by the increasing demand for new drugs to treat a variety of diseases, the rising cost of drug development, and the need to improve the efficiency of the drug discovery process. AI is being used to streamline every step of the drug discovery and development process, from target identification and molecule screening to preclinical and clinical testing. The benefits of using AI include accelerated development timelines, increased accuracy, and reduced costs.
Driving Forces: What's Propelling the AI for Drug Discovery and Development?
There are a number of factors driving the growth of the AI for drug discovery and development market. These include:
- The rising cost of drug development
- The need to improve the efficiency of the drug discovery process
- The increasing demand for new drugs to treat a variety of diseases
- The availability of large datasets
- The development of powerful AI algorithms
Challenges and Restraints in AI for Drug Discovery and Development
Despite the many benefits of using AI for drug discovery and development, there are also a number of challenges and restraints that need to be addressed. These include:
- The lack of data standards
- The difficulty in interpreting AI results
- The need for regulatory approval
- The cost of AI software and hardware
- The need for skilled AI personnel
Key Region or Country & Segment to Dominate the Market
The key region or country dominating the AI for drug discovery and development market is North America. This is due to the presence of a large number of pharmaceutical and biotechnology companies in the region. The United States is the largest market for AI for drug discovery and development, followed by Canada. The segment with the largest market share is target identification, followed by molecule screening.
Growth Catalysts in AI for Drug Discovery and Development Industry
There are a number of factors that are expected to drive the growth of the AI for drug discovery and development industry in the coming years. These include:
- The increasing demand for new drugs to treat a variety of diseases
- The rising cost of drug development
- The need to improve the efficiency of the drug discovery process
- The availability of large datasets
- The development of powerful AI algorithms
Leading Players in the AI for Drug Discovery and Development
- Alphabet
- Atomwise
- BenevolentAI
- Cloud Pharmaceutical
- Deep Genomics
- Exscientia
- IBM
- Insilico Medicine
- Microsoft Corporation
- Nvidia Corporation
- XtalPi
- DP Technology
- Tencent iDrug
- PaddleHelix
- EIHealth
- Aliyun
Significant Developments in AI for Drug Discovery and Development Sector
There have been a number of significant developments in the AI for drug discovery and development sector in recent years. These include:
- The development of new AI algorithms that are more powerful and accurate
- The availability of large datasets that can be used to train AI models
- The regulatory approval of AI-based drugs
- The increasing investment in AI for drug discovery and development by pharmaceutical and biotechnology companies
Comprehensive Coverage AI for Drug Discovery and Development Report
This report provides a comprehensive overview of the AI for drug discovery and development market. The report includes an analysis of the market size, key trends, drivers, restraints, and competitive landscape. The report also provides forecasts for the market size and growth rate.
AI for Drug Discovery and Development Segmentation
-
1. Type
- 1.1. Target Identification
- 1.2. Molecule Screening
- 1.3. De Novo Drug Design and Drug Optimization
- 1.4. Preclinical and Clinical Testing
- 1.5. Others
-
2. Application
- 2.1. Oncology
- 2.2. Infectious Disease
- 2.3. Neurology
- 2.4. Others
AI for Drug Discovery and Development Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. South America
- 2.1. Brazil
- 2.2. Argentina
- 2.3. Rest of South America
-
3. Europe
- 3.1. United Kingdom
- 3.2. Germany
- 3.3. France
- 3.4. Italy
- 3.5. Spain
- 3.6. Russia
- 3.7. Benelux
- 3.8. Nordics
- 3.9. Rest of Europe
-
4. Middle East & Africa
- 4.1. Turkey
- 4.2. Israel
- 4.3. GCC
- 4.4. North Africa
- 4.5. South Africa
- 4.6. Rest of Middle East & Africa
-
5. Asia Pacific
- 5.1. China
- 5.2. India
- 5.3. Japan
- 5.4. South Korea
- 5.5. ASEAN
- 5.6. Oceania
- 5.7. Rest of Asia Pacific
AI for Drug Discovery and Development REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 5% from 2019-2033 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.3. Market Restrains
- 3.4. Market Trends
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global AI for Drug Discovery and Development Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Type
- 5.1.1. Target Identification
- 5.1.2. Molecule Screening
- 5.1.3. De Novo Drug Design and Drug Optimization
- 5.1.4. Preclinical and Clinical Testing
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast - by Application
- 5.2.1. Oncology
- 5.2.2. Infectious Disease
- 5.2.3. Neurology
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. South America
- 5.3.3. Europe
- 5.3.4. Middle East & Africa
- 5.3.5. Asia Pacific
- 5.1. Market Analysis, Insights and Forecast - by Type
- 6. North America AI for Drug Discovery and Development Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Type
- 6.1.1. Target Identification
- 6.1.2. Molecule Screening
- 6.1.3. De Novo Drug Design and Drug Optimization
- 6.1.4. Preclinical and Clinical Testing
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast - by Application
- 6.2.1. Oncology
- 6.2.2. Infectious Disease
- 6.2.3. Neurology
- 6.2.4. Others
- 6.1. Market Analysis, Insights and Forecast - by Type
- 7. South America AI for Drug Discovery and Development Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Type
- 7.1.1. Target Identification
- 7.1.2. Molecule Screening
- 7.1.3. De Novo Drug Design and Drug Optimization
- 7.1.4. Preclinical and Clinical Testing
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast - by Application
- 7.2.1. Oncology
- 7.2.2. Infectious Disease
- 7.2.3. Neurology
- 7.2.4. Others
- 7.1. Market Analysis, Insights and Forecast - by Type
- 8. Europe AI for Drug Discovery and Development Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Type
- 8.1.1. Target Identification
- 8.1.2. Molecule Screening
- 8.1.3. De Novo Drug Design and Drug Optimization
- 8.1.4. Preclinical and Clinical Testing
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast - by Application
- 8.2.1. Oncology
- 8.2.2. Infectious Disease
- 8.2.3. Neurology
- 8.2.4. Others
- 8.1. Market Analysis, Insights and Forecast - by Type
- 9. Middle East & Africa AI for Drug Discovery and Development Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Type
- 9.1.1. Target Identification
- 9.1.2. Molecule Screening
- 9.1.3. De Novo Drug Design and Drug Optimization
- 9.1.4. Preclinical and Clinical Testing
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast - by Application
- 9.2.1. Oncology
- 9.2.2. Infectious Disease
- 9.2.3. Neurology
- 9.2.4. Others
- 9.1. Market Analysis, Insights and Forecast - by Type
- 10. Asia Pacific AI for Drug Discovery and Development Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by Type
- 10.1.1. Target Identification
- 10.1.2. Molecule Screening
- 10.1.3. De Novo Drug Design and Drug Optimization
- 10.1.4. Preclinical and Clinical Testing
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast - by Application
- 10.2.1. Oncology
- 10.2.2. Infectious Disease
- 10.2.3. Neurology
- 10.2.4. Others
- 10.1. Market Analysis, Insights and Forecast - by Type
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2024
- 11.2. Company Profiles
- 11.2.1 Alphabet
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Atomwise
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 BenevolentAI
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Cloud Pharmaceutical
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Deep Genomics
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Exscientia
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 IBM
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Insilico Medicine
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 Microsoft Corporation
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 Nvidia Corporation
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.11 XtalPi
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Financials (Based on Availability)
- 11.2.12 DP Technology
- 11.2.12.1. Overview
- 11.2.12.2. Products
- 11.2.12.3. SWOT Analysis
- 11.2.12.4. Recent Developments
- 11.2.12.5. Financials (Based on Availability)
- 11.2.13 Tencent iDrug
- 11.2.13.1. Overview
- 11.2.13.2. Products
- 11.2.13.3. SWOT Analysis
- 11.2.13.4. Recent Developments
- 11.2.13.5. Financials (Based on Availability)
- 11.2.14 PaddleHelix
- 11.2.14.1. Overview
- 11.2.14.2. Products
- 11.2.14.3. SWOT Analysis
- 11.2.14.4. Recent Developments
- 11.2.14.5. Financials (Based on Availability)
- 11.2.15 EIHealth
- 11.2.15.1. Overview
- 11.2.15.2. Products
- 11.2.15.3. SWOT Analysis
- 11.2.15.4. Recent Developments
- 11.2.15.5. Financials (Based on Availability)
- 11.2.16 Aliyun
- 11.2.16.1. Overview
- 11.2.16.2. Products
- 11.2.16.3. SWOT Analysis
- 11.2.16.4. Recent Developments
- 11.2.16.5. Financials (Based on Availability)
- 11.2.17
- 11.2.17.1. Overview
- 11.2.17.2. Products
- 11.2.17.3. SWOT Analysis
- 11.2.17.4. Recent Developments
- 11.2.17.5. Financials (Based on Availability)
- 11.2.1 Alphabet
List of Figures
- Figure 1: Global AI for Drug Discovery and Development Revenue Breakdown (million, %) by Region 2024 & 2032
- Figure 2: North America AI for Drug Discovery and Development Revenue (million), by Type 2024 & 2032
- Figure 3: North America AI for Drug Discovery and Development Revenue Share (%), by Type 2024 & 2032
- Figure 4: North America AI for Drug Discovery and Development Revenue (million), by Application 2024 & 2032
- Figure 5: North America AI for Drug Discovery and Development Revenue Share (%), by Application 2024 & 2032
- Figure 6: North America AI for Drug Discovery and Development Revenue (million), by Country 2024 & 2032
- Figure 7: North America AI for Drug Discovery and Development Revenue Share (%), by Country 2024 & 2032
- Figure 8: South America AI for Drug Discovery and Development Revenue (million), by Type 2024 & 2032
- Figure 9: South America AI for Drug Discovery and Development Revenue Share (%), by Type 2024 & 2032
- Figure 10: South America AI for Drug Discovery and Development Revenue (million), by Application 2024 & 2032
- Figure 11: South America AI for Drug Discovery and Development Revenue Share (%), by Application 2024 & 2032
- Figure 12: South America AI for Drug Discovery and Development Revenue (million), by Country 2024 & 2032
- Figure 13: South America AI for Drug Discovery and Development Revenue Share (%), by Country 2024 & 2032
- Figure 14: Europe AI for Drug Discovery and Development Revenue (million), by Type 2024 & 2032
- Figure 15: Europe AI for Drug Discovery and Development Revenue Share (%), by Type 2024 & 2032
- Figure 16: Europe AI for Drug Discovery and Development Revenue (million), by Application 2024 & 2032
- Figure 17: Europe AI for Drug Discovery and Development Revenue Share (%), by Application 2024 & 2032
- Figure 18: Europe AI for Drug Discovery and Development Revenue (million), by Country 2024 & 2032
- Figure 19: Europe AI for Drug Discovery and Development Revenue Share (%), by Country 2024 & 2032
- Figure 20: Middle East & Africa AI for Drug Discovery and Development Revenue (million), by Type 2024 & 2032
- Figure 21: Middle East & Africa AI for Drug Discovery and Development Revenue Share (%), by Type 2024 & 2032
- Figure 22: Middle East & Africa AI for Drug Discovery and Development Revenue (million), by Application 2024 & 2032
- Figure 23: Middle East & Africa AI for Drug Discovery and Development Revenue Share (%), by Application 2024 & 2032
- Figure 24: Middle East & Africa AI for Drug Discovery and Development Revenue (million), by Country 2024 & 2032
- Figure 25: Middle East & Africa AI for Drug Discovery and Development Revenue Share (%), by Country 2024 & 2032
- Figure 26: Asia Pacific AI for Drug Discovery and Development Revenue (million), by Type 2024 & 2032
- Figure 27: Asia Pacific AI for Drug Discovery and Development Revenue Share (%), by Type 2024 & 2032
- Figure 28: Asia Pacific AI for Drug Discovery and Development Revenue (million), by Application 2024 & 2032
- Figure 29: Asia Pacific AI for Drug Discovery and Development Revenue Share (%), by Application 2024 & 2032
- Figure 30: Asia Pacific AI for Drug Discovery and Development Revenue (million), by Country 2024 & 2032
- Figure 31: Asia Pacific AI for Drug Discovery and Development Revenue Share (%), by Country 2024 & 2032
List of Tables
- Table 1: Global AI for Drug Discovery and Development Revenue million Forecast, by Region 2019 & 2032
- Table 2: Global AI for Drug Discovery and Development Revenue million Forecast, by Type 2019 & 2032
- Table 3: Global AI for Drug Discovery and Development Revenue million Forecast, by Application 2019 & 2032
- Table 4: Global AI for Drug Discovery and Development Revenue million Forecast, by Region 2019 & 2032
- Table 5: Global AI for Drug Discovery and Development Revenue million Forecast, by Type 2019 & 2032
- Table 6: Global AI for Drug Discovery and Development Revenue million Forecast, by Application 2019 & 2032
- Table 7: Global AI for Drug Discovery and Development Revenue million Forecast, by Country 2019 & 2032
- Table 8: United States AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 9: Canada AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 10: Mexico AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 11: Global AI for Drug Discovery and Development Revenue million Forecast, by Type 2019 & 2032
- Table 12: Global AI for Drug Discovery and Development Revenue million Forecast, by Application 2019 & 2032
- Table 13: Global AI for Drug Discovery and Development Revenue million Forecast, by Country 2019 & 2032
- Table 14: Brazil AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 15: Argentina AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 16: Rest of South America AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 17: Global AI for Drug Discovery and Development Revenue million Forecast, by Type 2019 & 2032
- Table 18: Global AI for Drug Discovery and Development Revenue million Forecast, by Application 2019 & 2032
- Table 19: Global AI for Drug Discovery and Development Revenue million Forecast, by Country 2019 & 2032
- Table 20: United Kingdom AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 21: Germany AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 22: France AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 23: Italy AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 24: Spain AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 25: Russia AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 26: Benelux AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 27: Nordics AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 28: Rest of Europe AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 29: Global AI for Drug Discovery and Development Revenue million Forecast, by Type 2019 & 2032
- Table 30: Global AI for Drug Discovery and Development Revenue million Forecast, by Application 2019 & 2032
- Table 31: Global AI for Drug Discovery and Development Revenue million Forecast, by Country 2019 & 2032
- Table 32: Turkey AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 33: Israel AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 34: GCC AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 35: North Africa AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 36: South Africa AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 37: Rest of Middle East & Africa AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 38: Global AI for Drug Discovery and Development Revenue million Forecast, by Type 2019 & 2032
- Table 39: Global AI for Drug Discovery and Development Revenue million Forecast, by Application 2019 & 2032
- Table 40: Global AI for Drug Discovery and Development Revenue million Forecast, by Country 2019 & 2032
- Table 41: China AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 42: India AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 43: Japan AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 44: South Korea AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 45: ASEAN AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 46: Oceania AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
- Table 47: Rest of Asia Pacific AI for Drug Discovery and Development Revenue (million) Forecast, by Application 2019 & 2032
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.
Frequently Asked Questions
2. Which companies are prominent players in the AI for Drug Discovery and Development?
Key companies in the market include Alphabet, Atomwise, BenevolentAI, Cloud Pharmaceutical, Deep Genomics, Exscientia, IBM, Insilico Medicine, Microsoft Corporation, Nvidia Corporation, XtalPi, DP Technology, Tencent iDrug, PaddleHelix, EIHealth, Aliyun, .
3. What are the main segments of the AI for Drug Discovery and Development?
The market segments include Type, Application.
4. Can you provide details about the market size?
The market size is estimated to be USD 3555.5 million as of 2022.
5. What are some drivers contributing to market growth?
N/A
6. What are the notable trends driving market growth?
N/A
7. Are there any restraints impacting market growth?
N/A
8. Can you provide examples of recent developments in the market?
N/A
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4480.00, USD 6720.00, and USD 8960.00 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in million.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "AI for Drug Discovery and Development," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the AI for Drug Discovery and Development report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the AI for Drug Discovery and Development?
To stay informed about further developments, trends, and reports in the AI for Drug Discovery and Development, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.